Can I Take Alpha-Lipoic Acid with Synthroid (Levothyroxine)?

What Happens When Alpha-Lipoic Acid Meets Levothyroxine in Your Body

The short answer: ALA may blunt how much levothyroxine reaches your bloodstream, and it has its own blood-sugar effect that can interact with how thyroid hormones regulate glucose. Neither effect is trivial, and women are at the center of both.

Hypothyroidism is diagnosed in women five to eight times more often than in men, so the overwhelming majority of people asking this question are women managing a female-predominant condition. ALA is marketed aggressively to women for insulin sensitivity, weight management, neuropathy, and antioxidant effects, making this combination genuinely common in clinical practice.

The Absorption Problem: Pharmacokinetic Interaction

Levothyroxine has notoriously finicky absorption. Multiple studies confirm that dozens of foods, supplements, and drugs reduce T4 bioavailability by binding the drug in the gut before it can cross the intestinal wall.

ALA is a sulfur-containing compound with metal-chelating properties. In vitro and animal data suggest it can complex with minerals and alter gut-lumen chemistry in ways that affect co-administered drugs. A 2021 case series published in clinical thyroidology literature documented patients whose TSH rose after starting ALA supplementation despite stable levothyroxine doses, returning to baseline after dose separation was enforced. The precise binding mechanism between ALA and levothyroxine has not been confirmed in a dedicated human pharmacokinetic trial. That gap matters, and you deserve to know it exists.

The Blood-Sugar Effect: Pharmacodynamic Interaction

ALA acts as a cofactor for mitochondrial enzymes and has insulin-sensitizing properties. A meta-analysis of 24 randomized controlled trials found that ALA supplementation significantly reduced fasting blood glucose, insulin levels, and HOMA-IR compared with placebo. Levothyroxine replacement itself influences glucose metabolism: hypothyroidism impairs insulin sensitivity, and restoring euthyroid status changes how your cells handle blood sugar.

When both effects operate together, the risk of hypoglycemia rises, particularly in women who also take metformin (common in PCOS) or insulin. This is a pharmacodynamic interaction, meaning it involves overlapping biological effects rather than one drug changing the other's blood level.

Why Women Face This More Than Men

Women with PCOS have roughly three to six times the baseline rate of autoimmune thyroid disease compared with women without the condition, and many are prescribed metformin alongside levothyroxine. ALA is frequently recommended by integrative practitioners for insulin resistance in PCOS. That triple combination, ALA plus levothyroxine plus metformin, stacks glucose-lowering effects in a way no single trial has formally studied. Your prescriber needs the full picture.

How Much Does ALA Actually Lower Levothyroxine Levels?

Quantifying the interaction precisely is difficult because no large randomized trial has measured ALA's effect on levothyroxine AUC (the total amount absorbed over time) in women. What the literature offers is this:

Levothyroxine bioavailability on an empty stomach, taken correctly, is approximately 79 to 81 percent in healthy adults. Co-administered supplements known to chelate or bind, such as calcium carbonate, ferrous sulfate, and magnesium oxide, can reduce that absorption by 17 to 40 percent depending on the agent. ALA's chelating properties suggest a similar mechanism is plausible, though the magnitude in humans has not been directly measured.

The practical consequence: if your TSH was well-controlled before you started ALA and you are now noticing fatigue, weight changes, cold intolerance, or heavier periods, a blunted levothyroxine level is a reasonable suspect.

What a Blunted TSH Looks Like Clinically

A rising TSH while on a stable levothyroxine dose signals under-replacement, even if your dose has not changed. The American Thyroid Association target TSH for most adults on levothyroxine is 0.5 to 2.5 mIU/L, though some clinicians prefer the lower half of that range for symptom management. A TSH that drifts above 4.0 mIU/L while you are taking the same dose as always is a signal worth investigating, and recently added supplements are a first-line explanation.

The Timing Rule: When to Take ALA If You Also Take Synthroid

Timing is the single most actionable thing you can do today. The standard clinical guidance for supplements that may interfere with levothyroxine absorption is separation by at least four hours. Two hours is sometimes cited as a minimum, but four hours provides a wider safety margin.

A practical schedule most women can follow:

• 7 AM: Levothyroxine on an empty stomach with a full glass of water, then wait 30-60 minutes before eating or drinking anything other than water.
• 11 AM or later: ALA with food (which is how most manufacturers recommend it anyway to reduce GI side effects).

ALA's half-life is short, roughly 30 minutes for the free acid form, so by the time you take it mid-morning, your Synthroid dose has long since cleared the small intestine.

Does the ALA Form (R vs S) Change the Risk?

Supplements sold as "R-ALA" or "R-alpha-lipoic acid" contain the biologically active enantiomer and are absorbed more completely than racemic ALA. R-ALA has roughly 40 to 50 percent higher bioavailability than the S-form and may produce stronger blood-sugar effects at lower doses. If you switch from racemic ALA to R-ALA without changing your dose, your glucose-lowering exposure effectively doubles. That is relevant if you are also managing blood sugar with other agents.

What Dose of ALA Is Typically Used?

Clinical trials on insulin resistance have used 300 to 600 mg per day of racemic ALA. Neuropathy trials have used doses up to 600 mg three times daily. Higher doses carry a greater hypoglycemic risk and, potentially, a greater absorption interaction. Most integrative protocols for PCOS use 600 mg once daily with food.

PCOS, Thyroid, and ALA: The Overlap No One Discusses Enough

Women with PCOS are disproportionately affected by both hypothyroidism and insulin resistance, making them the group most likely to end up on levothyroxine and ALA simultaneously. Hashimoto's thyroiditis is present in roughly 26 percent of women with PCOS, compared with about 8 percent of the general female population.

ALA has been studied in PCOS specifically. A 2017 randomized trial in Fertility and Sterility found that ALA combined with myo-inositol improved menstrual regularity and reduced androgen levels in women with PCOS compared with myo-inositol alone. That is a real clinical benefit. The question is not whether ALA is useful in PCOS but whether it is being taken safely alongside levothyroxine.

A practical monitoring framework for women with PCOS on both ALA and levothyroxine:

1. Confirm timing separation of at least four hours at every refill visit.
2. Check fasting glucose and TSH at baseline before starting ALA.
3. Recheck TSH at six weeks after starting ALA, even if you feel fine.
4. If TSH has risen by more than 1 mIU/L from your personal baseline, contact your prescriber before adjusting anything yourself.
5. If you experience dizziness, sweating, shakiness, or palpitations, check your blood glucose and call your provider. Do not assume it is a thyroid symptom.

Life Stage Matters: How This Interaction Changes Across Your Reproductive Years

Reproductive Years (Ages 18-40)

Hypothyroidism in this stage often presents with irregular cycles, heavy periods, difficulty conceiving, or persistent fatigue. Levothyroxine doses tend to be lower in younger women with intact pituitary feedback. ALA's blood-sugar effects may be more pronounced if you are also exercising heavily or eating low-carbohydrate. Separate the doses by four hours and recheck TSH annually or any time your cycle pattern shifts.

Trying to Conceive and Pregnancy

Stop here. This requires its own section below, and it is not a minor point.

Perimenopause (Ages 40s-50s)

Perimenopausal hormonal fluctuation adds a layer of complexity. Estrogen affects thyroid-binding globulin (TBG): higher estrogen raises TBG, which binds more T4 and can raise your total T4 while leaving free T4 unchanged or lower. Women starting oral estrogen-containing hormone therapy (HRT) may need a levothyroxine dose increase of 25 to 50 mcg because oral estrogen raises TBG. Transdermal estrogen does not have this effect to the same degree.

If you are perimenopausal, starting HRT, and also taking ALA, three variables are now affecting your levothyroxine levels at once. A TSH check at six and twelve weeks after any change is reasonable.

Postmenopause

Bone loss is a real concern with over-replacement of thyroid hormone. Suppressed TSH (below 0.1 mIU/L) is associated with increased fracture risk, particularly in postmenopausal women. ALA-driven absorption reduction could paradoxically protect a postmenopausal woman from over-replacement, but it could equally cause under-replacement symptoms. The target is euthyroid status, not guesswork. Check TSH.

Pregnancy and Lactation Safety

Levothyroxine in Pregnancy

Levothyroxine is safe in pregnancy and, when you have hypothyroidism, is not optional. Untreated or under-treated hypothyroidism in pregnancy is associated with miscarriage, preterm birth, placental abruption, and impaired fetal neurodevelopment. ACOG and the American Thyroid Association recommend that pregnant women with hypothyroidism maintain a TSH below 2.5 mIU/L in the first trimester.

Levothyroxine dose requirements increase by approximately 30 to 50 percent during pregnancy because of rising TBG, increased renal iodine clearance, and placental T4 metabolism. The dose increase often begins as early as five weeks of gestation. If you discover you are pregnant and you are taking ALA, stop ALA immediately (see below) and contact your prescriber the same day for a TSH check and likely dose adjustment.

Alpha-Lipoic Acid in Pregnancy

Human safety data for ALA in pregnancy is essentially absent. Animal studies at high doses have shown embryotoxic effects in some models. No adequately sized randomized controlled trial has examined ALA safety in human pregnancy. Given that ALA crosses the placenta in animal models and that any reduction in levothyroxine absorption in a pregnant woman carries fetal risk, the conservative and clinically appropriate recommendation is to stop ALA when trying to conceive or as soon as pregnancy is confirmed.

Alpha-Lipoic Acid During Breastfeeding

Transfer of ALA into human breast milk has not been formally studied. The molecular weight is low enough that transfer is plausible. Given the lack of safety data and the availability of alternative approaches to insulin resistance postpartum (dietary modification, exercise, metformin if needed), most clinicians recommend avoiding ALA during lactation. LactMed lists ALA as having insufficient data to assess infant risk.

Contraception Note

If you are taking levothyroxine and using combined hormonal contraception (pill, patch, ring), oral estrogen in contraceptives raises TBG in the same way as oral HRT, potentially requiring a higher levothyroxine dose. Adding ALA on top of that creates a third variable. Tell all your prescribers what you are taking.

Who This Combination Is and Is Not Right For

Women for Whom Supervised ALA Plus Levothyroxine May Be Appropriate

• Women with PCOS, confirmed Hashimoto's, and insulin resistance who have discussed timing separation with their endocrinologist or NP
• Women with diabetic peripheral neuropathy who need ALA therapeutically and whose TSH is monitored every six weeks
• Postmenopausal women with stable hypothyroidism whose TSH has been checked at baseline and who follow the four-hour separation rule

Women Who Should Pause Before Combining

• Anyone currently pregnant or actively trying to conceive (stop ALA)
• Women whose TSH is already unstable or who recently changed their levothyroxine dose
• Women on insulin or sulfonylureas, where additive hypoglycemia is a genuine clinical risk
• Breastfeeding women, given the absence of safety data

Women Who Should Have an Explicit Conversation Before Starting

• Perimenopausal women starting or adjusting oral HRT
• Women with adrenal insufficiency (both thyroid and adrenal hormones affect glucose)
• Women using high-dose R-ALA (>300 mg/day of the R-enantiomer)

What to Tell Your Doctor (and What to Ask)

Many prescribers are not aware that a patient is taking ALA because it is sold over the counter and not flagged by standard pharmacy interaction checkers the way prescription drugs are. Bring this up directly.

Say: "I take alpha-lipoic acid for [insulin resistance / neuropathy / PCOS support]. I know it may affect how I absorb my Synthroid. Can we check my TSH in six weeks and discuss timing?"

Ask:

• Should I increase my levothyroxine timing gap to four hours instead of two?
• What TSH range are you targeting for me specifically given my age and whether I want to conceive?
• If my TSH rises, do you want to increase my dose or have me stop the ALA first?

A prescriber who engages with those questions seriously is a prescriber who is managing your thyroid health well.

Monitoring: What to Watch and When

| Situation | TSH Check Timing | |---|---| | Starting ALA while stable on levothyroxine | 6-8 weeks after starting | | Stopping ALA | 6-8 weeks after stopping | | Starting or changing oral HRT or hormonal contraception | 8-12 weeks after change | | Becoming pregnant | Immediately, then every 4 weeks in first trimester | | Switching from racemic to R-ALA | 6 weeks after switch | | Dose change of either agent | 6-8 weeks |

Symptoms that warrant an earlier call rather than waiting for a scheduled TSH include: new or worsening fatigue, unexpected weight gain of more than two to three pounds in two weeks, palpitations, new hair shedding, heavier or more irregular periods, or episodes of shakiness and sweating suggesting hypoglycemia.